Cytokinetics reports second quarter 2025 financial results and provides business update

Regulatory reviews of aficamten for obstructive hcm progressing in u.s., e.u. and china;  late-cycle meeting with u.s. fda scheduled for september ahead of december 26, 2025 pdufa date
CYTK Ratings Summary
CYTK Quant Ranking